Picture1.png
Autolus Therapeutics announces Board changes
January 20, 2023 07:00 ET | Autolus Therapeutics plc
LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two...
Picture1.png
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
January 09, 2023 07:00 ET | Autolus Therapeutics plc
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Picture1.png
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
December 21, 2022 16:01 ET | Autolus Therapeutics plc
LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today...
Picture1.png
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
December 12, 2022 10:00 ET | Autolus Therapeutics plc
Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...
Picture1.png
Autolus Announces Pricing of Public Offering
December 08, 2022 21:11 ET | Autolus Therapeutics plc
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Picture1.png
Autolus Announces Proposed Public Offering in the United States
December 08, 2022 16:03 ET | Autolus Therapeutics plc
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Picture1.png
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 08, 2022 16:02 ET | Autolus Therapeutics plc
Development milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus’ pivotal FELIX Phase 2 trial, announced in a separate press release...
Picture1.png
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
December 08, 2022 16:01 ET | Autolus Therapeutics plc
Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)Encouraging safety data observed,...
Picture1.png
Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
November 30, 2022 07:00 ET | Autolus Therapeutics plc
LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Picture1.png
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
November 03, 2022 09:31 ET | Autolus Therapeutics plc
obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...